Literature DB >> 21224822

Clinical management of doxorubicin-induced heart failure.

S Christiansen1.   

Abstract

Doxorubicin-induced heart failure is a rare but serious illness due to the well-known treatment difficulties. Prevention strategies have not demonstrated the expected success and unfortunately, this specific type of heart failure does not respond well to the usual medical therapy as other kinds of heart failure. Therefore, surgical procedures may be necessary in some patients. Cardiac transplantation is performed in most cases but it requires the cure of the neoplastic disease. This usually requires a recurrence-free interval of several years which is associated with a high attrition rate in these patients due to their cardiac disease. Therefore, ventricular assist devices were implanted in selected patients. This review presents the most common procedures and discusses their efficacy as well as their clinical applicability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21224822

Source DB:  PubMed          Journal:  J Cardiovasc Surg (Torino)        ISSN: 0021-9509            Impact factor:   1.888


  5 in total

Review 1.  Chemotherapy-induced cardiotoxicity.

Authors:  Amir Y Shaikh; Jeffrey A Shih
Journal:  Curr Heart Fail Rep       Date:  2012-06

2.  Berberine inhibits doxorubicin-triggered cardiomyocyte apoptosis via attenuating mitochondrial dysfunction and increasing Bcl-2 expression.

Authors:  Xiuxiu Lv; Xiaohui Yu; Yiyang Wang; Faqiang Wang; Hongmei Li; Yanping Wang; Daxiang Lu; Renbin Qi; Huadong Wang
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

3.  Protective effect of berberine on acute cardiomyopathy associated with doxorubicin treatment.

Authors:  Chen Xiong; Yan-Zhao Wu; Yu Zhang; Zi-Xiao Wu; Xue-Yan Chen; Ping Jiang; Hui-Cai Guo; Ke-Rang Xie; Ke-Xin Wang; Su-Wen Su
Journal:  Oncol Lett       Date:  2018-02-09       Impact factor: 2.967

4.  Berberine Ameliorates Doxorubicin-Induced Cardiotoxicity via a SIRT1/p66Shc-Mediated Pathway.

Authors:  Yan-Zhao Wu; Lan Zhang; Zi-Xiao Wu; Tong-Tong Shan; Chen Xiong
Journal:  Oxid Med Cell Longev       Date:  2019-12-06       Impact factor: 6.543

5.  Fisetin Attenuates Doxorubicin-Induced Cardiomyopathy In Vivo and In Vitro by Inhibiting Ferroptosis Through SIRT1/Nrf2 Signaling Pathway Activation.

Authors:  Danlei Li; Xiaoman Liu; Wenhu Pi; Yang Zhang; Lei Yu; Cheng Xu; Zhenzhu Sun; Jianjun Jiang
Journal:  Front Pharmacol       Date:  2022-02-22       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.